NASDAQ:AGEN - Nasdaq - US00847G8042 - Common Stock - Currency: USD
3.32
-0.13 (-3.77%)
The current stock price of AGEN is 3.32 USD. In the past month the price decreased by -11.7%. In the past year, price decreased by -75.66%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.97 | 357.10B | ||
AMGN | AMGEN INC | 15.29 | 162.72B | ||
GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
NTRA | NATERA INC | N/A | 21.43B | ||
BIIB | BIOGEN INC | 8.54 | 20.49B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Agenus Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Lexington, Massachusetts and currently employs 389 full-time employees. The company went IPO on 2000-02-04. Agenus Inc. is an immuno-oncology (I-O) company targeting cancer and infectious diseases with a pipeline of immunological agents. The company is specialized in developing therapies to activate the body's immune system against cancer and infections. Its pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is I-O, and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody (AGEN1811)) and balstilimab (a programmed death receptor-1 (PD-1) blocking antibody). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.
AGENUS INC
3 Forbes Rd
Lexington MASSACHUSETTS 02421 US
CEO: Garo H. Armen
Employees: 389
Company Website: https://agenusbio.com/
Investor Relations: https://investor.agenusbio.com/
Phone: 17816744400
The current stock price of AGEN is 3.32 USD. The price decreased by -3.77% in the last trading session.
The exchange symbol of AGENUS INC is AGEN and it is listed on the Nasdaq exchange.
AGEN stock is listed on the Nasdaq exchange.
11 analysts have analysed AGEN and the average price target is 8.16 USD. This implies a price increase of 145.78% is expected in the next year compared to the current price of 3.32. Check the AGENUS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
AGENUS INC (AGEN) has a market capitalization of 77.89M USD. This makes AGEN a Micro Cap stock.
AGENUS INC (AGEN) currently has 389 employees.
AGENUS INC (AGEN) has a support level at 3.2 and a resistance level at 3.34. Check the full technical report for a detailed analysis of AGEN support and resistance levels.
The Revenue of AGENUS INC (AGEN) is expected to decline by -10.52% in the next year. Check the estimates tab for more information on the AGEN EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
AGEN does not pay a dividend.
AGENUS INC (AGEN) will report earnings on 2025-03-12, after the market close.
AGENUS INC (AGEN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-11.24).
The outstanding short interest for AGENUS INC (AGEN) is 12.65% of its float. Check the ownership tab for more information on the AGEN short interest.
ChartMill assigns a technical rating of 1 / 10 to AGEN. When comparing the yearly performance of all stocks, AGEN is a bad performer in the overall market: 93.17% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to AGEN. AGEN may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months AGEN reported a non-GAAP Earnings per Share(EPS) of -11.24. The EPS increased by 31.46% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -95.55% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 75% to AGEN. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of 12.65% and a revenue growth -10.52% for AGEN